Chris Ashton

Chris is a non-executive Director of OMass Therapeutics. He has been an advisor to Oxford Science Enterprises since December 2019 and serves as Chairman of the Board of PepGen. He is a seasoned biotech entrepreneur with over 35 years’ experience in the biotechnology industry. Chris has considerable expertise in leading and growing early stage companies and enabling their transition to mid-stage clinical development organisations. He has extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris was formerly a Partner at Syncona, a FTSE 250 company, where he was also founding CEO of Achilles Therapeutics. Prior to that he was CEO of Argenta Discovery (sold to Galapagos) and Pulmagen Therapeutics. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).